Hampig Raphaël Kourie (Hampig R Kourie, Hampig Raphael Kourie)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Systematic Review

Papillary Thyroid

Tyrosine Kinase

Mesenchymal Stem Cells

Top Venues

Pharmacogenomics

Future oncology (London, England)

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Fouad Attieh, Marc Boutros, Hampig Raphaël Kourie, Mervat Mahrous
Turning the tide: pembrolizumab's triumph in adjuvant RCC therapy. Medical oncology (Northwood, London, England) 41 (10) (2024)
John-Victor El Khoury, Sophie Wehbe, Fouad Attieh, Marc Boutros, Carole Kesrouani, Hampig Raphaël Kourie
A critical review of RAF inhibitors in BRAF-mutated glioma treatment. Pharmacogenomics (2024)
Fouad Attieh, Hampig Raphaël Kourie
Breaking barriers: the latest insights into KRAS G12C inhibitors. Future oncology (London, England) (2024)
Antoine Mouawad, Sofia Habib, Marc Boutros, Fouad Attieh, Hampig Raphaël Kourie
How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer. Future oncology (London, England) (2024)
Antoine Chartouni, Antoine Mouawad, Marc Boutros, Fouad Attieh, Nicolas Medawar, Hampig Raphaël Kourie
Mesenchymal stem cells: a trojan horse to treat glioblastoma. Investigational new drugs (2023)
Fouad Attieh, Antoine Chartouni, Marc Boutros, Antoine Mouawad, Hampig Raphaël Kourie
Tackling the immunotherapy conundrum: advances and challenges for operable non-small-cell lung cancer treatment. Immunotherapy (2023)
Marc Boutros, Fouad Attieh, Antoine Chartouni, Johnny Jalbout, Hampig Raphaël Kourie
Beyond the Horizon: A Cutting-Edge Review of the Latest Checkpoint Inhibitors in Cancer Treatment for 2022. Cancer investigation (2023)
Mariana Boulos, Elissar Moujaes, Ghazi Nsouli, Arafat Tfayli, Hampig Raphaël Kourie
Talazoparib in BRCA -mutated advanced breast cancer: is earlier better? Pharmacogenomics 23 (8) (2022)
Hampig Raphaël Kourie, Fahad Ibnshamsah, Joseph Zouein, Nabih Naim, Salah Abbasi, Nasr Allahloubi, Manwar Al-Naqqash, Ashwaq Alolayan, Ahmed Alshehri, Nizar Bitar, Adda Bounedjar, Abdulaziz Al Farsi, Humaid El Shamsi, Ramy Ghali, Hassan Jaafar, Blaha Larbaoui, Mervat Mahrous, Hind Mrabti, Abdul Razzak Nweir, Mohamed Oukkal, Kakil Rasul, Mohsen Razavi, Rim Turfa, Sami Khatib, Ali Shamseddine
The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. Future oncology (London, England) 18 (24) (2022)
Tarek Souaid, Joya-Rita Hindy, Ernest Diab, Hampig Raphaël Kourie
Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities? Pharmacogenomics 22 (10) (2021)
Khalil El Gharib, Makram Khoury, Hampig Raphaël Kourie
HER2 in gastric adenocarcinoma: where do we stand today? Personalized medicine (2021)
Joseph Zouein, Fady Gh Haddad, Roland Eid, Hampig Raphaël Kourie
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy (2021)
Khalil El Gharib, Hampig Raphaël Kourie
NTRK genes and cancer: when arresting the fusion underlies the treatment. Epigenomics 13 (8) (2021)
Elissar Moujaes, Hampig Raphaël Kourie, Joseph Kattan
Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing? Pharmacogenomics 21 (11) (2020)
Khalil El Gharib, Hampig Raphaël Kourie
Is ramucirumab still the only second-line treatment in metastatic gastric cancer? Pharmacogenomics 21 (17) (2020)